Stock IONS IONIS PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Ionis Pharmaceuticals, Inc.

Equities

IONS

US4622221004

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-29 pm EDT 		5-day change 1st Jan Change
41.99 USD +0.96% Intraday chart for Ionis Pharmaceuticals, Inc. +2.24% -17.00%
Apr. 11 North American Morning Briefing : Stock Futures -2- DJ
Apr. 10 Wolfe Research Upgrades Ionis Pharmaceuticals to Outperform From Peer Perform MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Ionis Publishes 2023 Corporate Responsibility Report
PR
Ionis to hold first quarter 2024 financial results webcast
PR
Ionis Pharmaceuticals : Listen to webcast
PU
Ionis presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndrome
AQ
Ionis to present at upcoming investor conferences
PR
Ionis Pharmaceuticals - Positive olezarsen Phase 3 data in familial chylomicronemia syndrome to be presented at 2024 American College of Cardiology annual meeting
AQ
Ionis announces positive results from Phase 2 study of ION224, an investigational medicine demonstrating clinical efficacy in the treatment of NASH/MASH
PR
Ionis announces new chief global product strategy officer to lead next phase of commercial growth
PR
Ionis to present at upcoming investor conferences
PR
Ionis Pharmaceuticals: Q4 Earnings Snapshot
AQ
Ionis reports fourth quarter and full year 2023 financial results
PR
Olezarsen receives Orphan Drug designation from U.S. FDA for familial chylomicronemia syndrome
PR
Ionis Pharmaceuticals - Eplontersen granted U.S. FDA Fast Track designation for patients with transthyretin-mediated amyloid cardiomyopathy
AQ
Eplontersen granted U.S. FDA Fast Track designation for patients with transthyretin-mediated amyloid cardiomyopathy
PR
Ionis to hold fourth quarter and full year 2023 financial results webcast
PR
Ionis announces positive topline results from Phase 3 OASIS-HAE study of investigational donidalorsen in patients with hereditary angioedema
PR
Ionis poised for continued momentum in 2024 with product launches and key advances in robust pipeline of investigational medicines for serious diseases
PR
Ionis to present at 42nd Annual J.P. Morgan Healthcare Conference
PR
Ionis Pharmaceuticals signs license agreement with Otsuka Pharmaceutical
AQ
Ionis announces European licensing agreement with Otsuka for donidalorsen in hereditary angioedema
PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. IONS Stock
  4. News Ionis Pharmaceuticals, Inc.
  5. Press Releases